Microbot Medical (NASDAQ:MBOT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Microbot Medical (NASDAQ:MBOT) from a strong sell rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently commented on the company. B. Riley Financial started coverage on Microbot Medical in a report on Friday, September 11th. They set a “buy” rating and a $4.00 target price for the company. Zacks Research downgraded Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating on shares of Microbot Medical in a research note on Wednesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, July 8th. Finally, Loop Capital set a $4.00 target price on shares of Microbot Medical in a research report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.38.

Microbot Medical Stock Performance

NASDAQ MBOT opened at $1.35 on Friday. The stock has a market capitalization of $90.68 million, a P/E ratio of -5.63 and a beta of 1.03. Microbot Medical has a 1 year low of $1.34 and a 1 year high of $3.74. The business’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.95.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. On average, research analysts forecast that Microbot Medical will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Microbot Medical

Several hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 71,560 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Microbot Medical by 44.7% during the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 13,099 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Microbot Medical during the fourth quarter worth approximately $65,000. Private Advisor Group LLC purchased a new position in Microbot Medical during the first quarter valued at approximately $54,000. Finally, CTC Alternative Strategies Ltd. purchased a new position in Microbot Medical during the first quarter valued at approximately $28,000. 16.30% of the stock is owned by hedge funds and other institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc is a medical-device company focused on developing robotic and computer-assisted technologies for minimally invasive vascular procedures. The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use system designed to enable physicians to remotely control the navigation and positioning of guidewires and catheters during endovascular interventions.

LIBERTY is intended to support procedures involving the peripheral and coronary vasculature while potentially reducing physician exposure to radiation and improving procedural control.